Pediatric Exploratory Research Study of EGCG Use and Safety (PERSEUS)

NCT ID: NCT03624556 Phase: NA Status: COMPLETED Enrollment: 76 Completion: 2020-11-30

Conditions

Down Syndrome, Fragile X Syndrome

Interventions

EGCG FontUp, Placebo FontUp

Summary

To evaluate safety and tolerability of epigallocatechin gallate (EGCG) in children from 6 to 12 years old with Intellectual Developmental Disorders (IDD) (Down syndrome or Fragile X syndrome).

Primary Outcome

Safety Outcome Measure : Adverse Events

Source

ClinicalTrials.gov